Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CADL

Candel Therapeutics Inc

Apr 23 • 04:00PM ET

5.91

Dollar change +0.37
Percentage change 6.68	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.31	Insider Own	46.65%	Shs Outstand	29.21M	Perf Week	0.34%
Market Cap	173.46M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	15.66M	Perf Month	294.00%
Income	-37.94M	PEG	-	EPS next Q	-	Inst Own	5.76%	Short Float	1.03%	Perf Quarter	347.73%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-0.71%	Short Ratio	0.03	Perf Half Y	556.67%
Book/sh	0.44	P/B	13.55	EPS next Y	-	ROA	-63.12%	Short Interest	0.16M	Perf Year	322.14%
Cash/sh	1.21	P/C	4.90	EPS next 5Y	-	ROE	-125.50%	52W Range	0.66 - 11.40	Perf YTD	302.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.75%	ROI	-145.35%	52W High	-48.16%	Beta	-0.55
Dividend TTM	-	Quick Ratio	2.59	Sales past 5Y	-25.00%	Gross Margin	-3654.84%	52W Low	795.45%	ATR (14)	0.93
Dividend Ex-Date	-	Current Ratio	2.59	EPS Y/Y TTM	-101.37%	Oper. Margin	0.00%	RSI (14)	63.33	Volatility	11.48% 31.12%
Employees	42	Debt/Eq	1.79	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	11.00
Option/Short	Yes / Yes	LT Debt/Eq	1.05	EPS Q/Q	-117.62%	Payout	-	Rel Volume	0.08	Prev Close	5.54
Sales Surprise	-	EPS Surprise	-137.50%	Sales Q/Q	-100.00%	Earnings	Mar 28 BMO	Avg Volume	5.27M	Price	5.91
SMA20	34.06%	SMA50	115.69%	SMA200	290.26%	Trades		Volume	447,473	Change	6.68%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-22	Initiated	H.C. Wainwright	Buy	$11
Nov-19-21	Initiated	BMO Capital Markets	Outperform	$18
Aug-23-21	Initiated	UBS	Buy	$9
Aug-23-21	Initiated	Jefferies	Buy	$22
Aug-23-21	Initiated	Credit Suisse	Outperform	$15

Apr-12-24 10:00AM	Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag (Zacks) -8.52%
Apr-11-24 09:00AM	Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer (GlobeNewswire) +42.75%
Apr-09-24 08:00AM	Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors (GlobeNewswire) -20.84%
Apr-05-24 12:10PM	Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study (Zacks)
Apr-04-24 12:24PM	After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study (Benzinga) +280.95%
08:00AM	Loading…
08:00AM	Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire)
Mar-28-24 04:05PM	Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma (GlobeNewswire)
01:53PM	CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
08:05AM	Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-15-24 08:15AM	Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors (News Direct)
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 04:30PM	Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate (GlobeNewswire)
Feb-13-24 07:30AM	CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma (GlobeNewswire) +29.50%
Feb-05-24 08:00AM	Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts (GlobeNewswire)
Dec-13-23 12:21PM	Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409 (Zacks) +17.82%
08:00AM	Loading…
Dec-12-23 08:00AM	Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer (GlobeNewswire) +16.29%
Nov-28-23 09:00AM	Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN Discovery Platform, and Key Clinical Readouts for CAN-2409 (GlobeNewswire) -8.16%
Nov-09-23 09:43AM	Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical Progress (GuruFocus.com) -13.00%
08:00AM	Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-04-23 08:00AM	Candel Therapeutics Presents Preclinical Data from its enLIGHTEN Discovery Platform at SITC (GlobeNewswire)
Nov-03-23 12:00PM	Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire) -21.50%
Oct-18-23 11:00AM	Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110 (GlobeNewswire)
Sep-27-23 09:40AM	Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting (GlobeNewswire) -9.00%
Sep-26-23 08:00AM	Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer (GlobeNewswire) -10.71%
Sep-06-23 08:00AM	Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 08:00AM	Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-02-23 08:00AM	Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jun-13-23 08:00AM	Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024 (GlobeNewswire)
Jun-08-23 08:00AM	Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors (GlobeNewswire) +5.30%
Jun-05-23 08:00AM	Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (GlobeNewswire) +9.80%
08:26AM	Loading…
May-22-23 08:26AM	Favourable Signals For Candel Therapeutics: Numerous Insiders Acquired Stock \ (Simply Wall St.) +7.64%
May-19-23 01:51PM	Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer (Benzinga) -8.15%
09:00AM	Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire)
May-11-23 08:00AM	Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-02-23 08:00AM	Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO (GlobeNewswire) +15.44%
Apr-17-23 08:00AM	Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer (GlobeNewswire) +19.01%
Mar-30-23 08:00AM	Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research) +5.54%
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research) +6.46%
Mar-06-23 07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research)
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research)
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
Feb-28-23 06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research) -9.01%
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-24-23 07:17AM	Daily Vickers Top Insider Picks for 02/24/2023 (Argus Research)
Feb-23-23 07:21AM	Daily Vickers Top Insider Picks for 02/23/2023 (Argus Research)
Feb-22-23 06:56AM	Daily Vickers Top Insider Picks for 02/22/2023 (Argus Research) -5.28%
Feb-21-23 07:35AM	Daily Vickers Top Insider Picks for 02/21/2023 (Argus Research)
Feb-17-23 06:27AM	Daily Vickers Top Insider Picks for 02/17/2023 (Argus Research)
Feb-16-23 07:28AM	Daily Vickers Top Insider Picks for 02/16/2023 (Argus Research)
Feb-15-23 07:01AM	Daily Vickers Top Insider Picks for 02/15/2023 (Argus Research)
Feb-14-23 06:23AM	Daily Vickers Top Insider Picks for 02/14/2023 (Argus Research)
Feb-13-23 07:30AM	Daily Vickers Top Insider Picks for 02/13/2023 (Argus Research)
Feb-10-23 06:42AM	Daily Vickers Top Insider Picks for 02/10/2023 (Argus Research) -8.86%
Feb-09-23 06:51AM	Daily Vickers Top Insider Picks for 02/09/2023 (Argus Research)
Feb-08-23 06:45AM	Daily Vickers Top Insider Picks for 02/08/2023 (Argus Research)
Feb-07-23 06:46AM	Daily Vickers Top Insider Picks for 02/07/2023 (Argus Research)
Feb-06-23 06:56AM	Daily Vickers Top Insider Picks for 02/06/2023 (Argus Research) -6.20%
Feb-03-23 06:32AM	Daily Vickers Top Insider Picks for 02/03/2023 (Argus Research)
Feb-02-23 06:43AM	Daily Vickers Top Insider Picks for 02/02/2023 (Argus Research)
Feb-01-23 08:00AM	Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day (GlobeNewswire) -6.21%
06:14AM	Daily Vickers Top Insider Picks for 02/01/2023 (Argus Research)
Jan-31-23 06:50AM	Daily Vickers Top Insider Picks for 01/31/2023 (Argus Research) +6.62%
Jan-30-23 06:42AM	Daily Vickers Top Insider Picks for 01/30/2023 (Argus Research) -9.74%
Jan-27-23 07:00AM	Daily Vickers Top Insider Picks for 01/27/2023 (Argus Research) +6.80%
Jan-26-23 06:44AM	Daily Vickers Top Insider Picks for 01/26/2023 (Argus Research) +6.16%
Jan-25-23 06:39AM	Daily Vickers Top Insider Picks for 01/25/2023 (Argus Research) -11.80%
Jan-24-23 06:48AM	Daily Vickers Top Insider Picks for 01/24/2023 (Argus Research)
Jan-23-23 06:58AM	Daily Vickers Top Insider Picks for 01/23/2023 (Argus Research) +14.29%
Jan-20-23 06:55AM	Daily Vickers Top Insider Picks for 01/20/2023 (Argus Research) +5.77%
Jan-19-23 06:43AM	Daily Vickers Top Insider Picks for 01/19/2023 (Argus Research) +8.18%
Jan-18-23 06:28AM	Daily Vickers Top Insider Picks for 01/18/2023 (Argus Research) -5.45%
Jan-17-23 06:27AM	Daily Vickers Top Insider Picks for 01/17/2023 (Argus Research) +5.77%
Jan-13-23 06:56AM	Daily Vickers Top Insider Picks for 01/13/2023 (Argus Research) +5.58%
Jan-12-23 08:00AM	Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference (GlobeNewswire)
06:50AM	Daily Vickers Top Insider Picks for 01/12/2023 (Argus Research)
Jan-11-23 06:53AM	Daily Vickers Top Insider Picks for 01/11/2023 (Argus Research) +10.34%
Jan-09-23 06:31AM	Daily Vickers Top Insider Picks for 01/09/2023 (Argus Research)
Jan-06-23 06:49AM	Daily Vickers Top Insider Picks for 01/06/2023 (Argus Research) -10.41%
Jan-04-23 06:54AM	Daily Vickers Top Insider Picks for 01/04/2023 (Argus Research) +12.43%
Jan-03-23 06:26AM	Daily Vickers Top Insider Picks for 01/03/2023 (Argus Research)
Dec-30-22 07:17AM	Daily Vickers Top Insider Picks for 12/30/2022 (Argus Research) +7.83%
Dec-29-22 06:51AM	Daily Vickers Top Insider Picks for 12/29/2022 (Argus Research) +8.50%
Dec-28-22 06:58AM	Daily Vickers Top Insider Picks for 12/28/2022 (Argus Research)
Dec-27-22 07:11AM	Daily Vickers Top Insider Picks for 12/27/2022 (Argus Research)
Dec-23-22 06:32AM	Daily Vickers Top Insider Picks for 12/23/2022 (Argus Research) -12.14%
Dec-22-22 06:34AM	Daily Vickers Top Insider Picks for 12/22/2022 (Argus Research) +7.45%
Dec-21-22 06:46AM	Daily Vickers Top Insider Picks for 12/21/2022 (Argus Research) -5.29%
Dec-20-22 06:29AM	Daily Vickers Top Insider Picks for 12/20/2022 (Argus Research)
Dec-19-22 08:09AM	Daily Vickers Top Insider Picks for 12/19/2022 (Argus Research)
Dec-13-22 05:11AM	The Independent Director of Candel Therapeutics, Inc. (NASDAQ:CADL), Joseph Papa, Just Bought A Few More Shares (Simply Wall St.) -7.36%
Dec-06-22 04:26PM	Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer (GlobeNewswire) -13.02%
Nov-29-22 08:00AM	Candel Therapeutics to Host Virtual R&D Day on December 6, 2022 (GlobeNewswire)
Nov-18-22 08:00AM	Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting (GlobeNewswire)
Nov-11-22 12:00PM	Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma (GlobeNewswire)
Nov-10-22 08:00AM	Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +10.67%
Nov-07-22 08:00AM	Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO (GlobeNewswire) +9.68%
Nov-01-22 08:00AM	Candel Therapeutics Upcoming Investor Conference Participation for November (GlobeNewswire)
Oct-27-22 11:16AM	Penn Medicine and Boston-area biopharm firm to pursue potential solid tumor CAR T-cell therapy (American City Business Journals) +5.26%

Candel Therapeutics, Inc. is a late clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CADL

Candel Therapeutics Inc

Upgrade your FINVIZ experience